Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Hence, we strongly encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with uncontrolled metabolic risks, i.e., especially those who need to lose weight and/or control high blood pressure
Current evidence suggests that ispaghula husk may contribute to a modest enhancement of endogenous GLP-1 secretion , likely mediated through viscosity effects, delayed gastric emptying, and possibly some SCFA production
Ultimately, these drugs alone wont improve overall metabolic health
Some patients reach their health and weight loss goals on medication alone and stay on it long-term
J Clin Invest 124: 2456-2463, 2014
US$ 21.39
US$ 22.58
US$ 26.60
US$ 20.57
